CYTK Q1 2024 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$835,000-81.9% YoY

Gross Profit

-$81M-9668.9% margin

Operating Income

-$126M-15118.0% margin

Net Income

-$136M-16244.7% margin

EPS (Diluted)

$-1.33

QoQ Revenue Growth

-50.1%

Cash Flow

Operating Cash Flow

-$130M

Free Cash Flow

-$128M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$808M

Total Liabilities

$1.2B

Stockholders' Equity

-$396M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$835,000	$5M	-81.9%
Gross Profit	-$81M	-$75M	-7.9%
Operating Income	-$126M	-$124M	-1.4%
Net Income	-$136M	-$131M	-3.3%

Revenue Segments

Research And Development

$835,000100%